WHO Sounds Alert Over Acute Shortage of Obesity Jabs

Under one in 10 people who could benefit from GLP-1 drugs like Wegovy are able to get them, warns the World Health Organization as it publishes its inaugural recommendations on the medications.

With in excess of 1,000,000,000 people worldwide currently obese, it is advocating for increased and just availability to these injectable treatments.

According to forecasts, in excess of 2,000,000,000 will be obese by 2030 unless action is taken.

"The new guidelines acknowledges that excess weight is a long-term condition that can be addressed with holistic and lifelong care," said the agency's head Tedros Adhanom Ghebreyesus.

High costs, insufficient output, and distribution challenges are significant obstacles to widespread access to the jabs that can assist patients in reducing substantial weight, notes the body.

GLP-1 Therapy Scarcity

Even in the present most optimistic scenario, the supply of these medications could only cover approximately 100 million people – less than 10% of eligible patients, per the health organization.

The guideline urges governments and firms to expand access, through strategies such as voluntary licensing.

Exclusive production rights on semaglutide – the core ingredient of a leading brand – is scheduled to end in a number of nations in 2026.

How Weight-Loss Drugs Work

GLP-1 drugs mimick a biological compound to slow digestion, curb appetite and boost feelings of fullness so individuals reduce food intake.

Patients usually begin shedding pounds in the initial weeks of beginning the once-weekly jabs.

Research indicates patients may regain a significant portion after a year of halting the medication, because their typical hunger return.

To be above a healthy weight raises your likelihood for experiencing diseases, like type 2 diabetes, cardiovascular issues, stroke, and specific malignancies.

Obesity affects individuals in every country and was responsible for 3.7 million fatalities worldwide in 2024, per the health agency.